# Cerecin Pte.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cerecin-pte

- Industry: Biotechnology
- Headquarters: Singapore, Singapore
- Website: www.cerecin.com
- Total disclosed funding: $107M
- Latest round: Series B (Aug 3, 2022)
- Investors on record: 15

## About

Cerecin Pte. Ltd. is a healthcare company focused on brain health, developing innovative products aimed at treating neurological disorders, particularly Alzheimer’s disease and migraines.Founded in 2001 and headquartered in Singapore, Cerecin Pte. Ltd. specializes in healthcare solutions targeting brain health. The company raised USD 7.22 million in Series B funding on August 3, 2022, co-led by K&T Partners and SK Securities. Charles Stacey serves as the CEO, overseeing the company’s strategic initiatives.Cerecin Neurosciences specializes in innovative healthcare solutions focused on brain health, primarily leveraging the physiological ketone system to provide energy for the brain. Their core product offerings include tricaprilin, which is under investigation in the Phase 3 ALTER AD clinical trial aimed at treating mild to moderate Alzheimer's disease, as well as CER-0001, a ketogenic investigational agent targeting migraine treatment. These products are designed to address significant unmet medical needs in neurological disorders, catering to both patients suffering from these conditions and healthcare providers seeking effective treatment options. Cerecin distributes its products in various geographical markets, including the United States, Singapore, Australia, and South Korea, thereby contributing to a wider global focus on neurological health solutions.Cerecin Neurosciences generated revenue of USD 8,603,671 in 2023, with an EBITDA of USD 3,320,310. The company operates on a B2B model, partnering with healthcare providers and research institutions to advance their therapeutic pipelines. Their revenue structure is anticipated to include direct sales to healthcare institutions as their products progress through clinical trials and toward market availability.In August 2022, Cerecin Pte. Ltd. raised USD 7.22 million in Series B funding to further develop its clinical studies and products. The company plans to introduce new products aimed at treating neurological disorders and expand into new markets, specifically targeting regions across Asia and beyond. These initiatives demonstrate Cerecin's commitment to enhancing its therapeutic offerings and addressing emerging global health challenges.

## Funding rounds

- Series B, Aug 3, 2022, $7.2M — SK Securities, K&T Partners
- Series A, Oct 19, 2021, $40M — M Capital, KB Financial Group, Shinhan Securities, Partners Investment, IBK Capital, Medici Investment, KT Investment, Hana Securities, Wilmar Ventures, Arche Investments Ltd, SK Securities
- Series D, Dec 7, 2010, $11M — Inventages Venture Capital, POSCO BioVentures, Bloodstone Ventures
- Series C, Nov 11, 2008, $35M — Inventages Venture Capital, POSCO BioVentures
- Series B, Aug 16, 2006, $7.5M — Inventages Venture Capital, POSCO BioVentures
- Series A, Sep 16, 2004, $6M — Inventages Venture Capital, POSCO BioVentures

## Investors

- Inventages Venture Capital (https://capitalatlas.ai/funds/inventages-venture-capital) — Series A, Series B, Series C, Series D
- POSCO BioVentures (https://capitalatlas.ai/funds/posco-bioventures) — Series A, Series B, Series C, Series D
- Bloodstone Ventures — Series D
- M Capital (https://capitalatlas.ai/funds/m-capital) — Series A
- KB Financial Group — Series A
- Shinhan Securities (https://capitalatlas.ai/funds/shinhan-securities) — Series A
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series A
- IBK Capital (https://capitalatlas.ai/funds/ibk-capital) — Series A
- Medici Investment (https://capitalatlas.ai/funds/medici-investment) — Series A
- KT Investment (https://capitalatlas.ai/funds/kt-investment) — Series A
- Hana Securities (https://capitalatlas.ai/funds/hana-securities) — Series A
- Wilmar Ventures — Series A
- Arche Investments Ltd — Series A
- SK Securities — Series A, Series B
- K&T Partners (https://capitalatlas.ai/funds/k-t-partners) — Series B